Another example is the co-administration of the EGFR-TKI osimertinib and T-DM1, which contributed to an synergistic anti-tumor effect, where T-DM1 was able to delay or overcome osimertinib resistance in EGFR-mutant NSCLC models [105]. This evidence concerns the gene EGFR and neoplasm.